Drugs Made In America Acquisition II Corp. Ordinary Shares
DMIINASDAQFinancial ServicesFinancial - Conglomerates
Previous close
$10.14
$0.00 · 0.00%
DMII company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
85
Deep Value
Momentum
40
Weakening
Sentiment
55
Mixed
Risk resilience
92
Low Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteDrugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.
- Industry
- Financial - Conglomerates
- Sector
- Financial Services
- Headquarters
- US
- CEO
- Roger Bendelac
- Listed since
- Dec 4, 2025
- Employees
- 2
Market position
52-week range
Current $10.14
- Open
- $10.14
- Previous close
- $10.14
- Volume
- 1.06K
- 0.01× average
- Average volume
- 114.07K
- Average daily volume
- Market cap
- 645.92M USD
- Beta
- 0.04
- Market reference 1
- 50-day average
- $10.0993
- +0.40% above average
- 200-day average
- $10.0107
- +1.29% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 131.55M USD
- P/E (TTM)
- 0.44×
- P/B (TTM)
- 0.01×
- P/S (TTM)
- 0×
- EV / EBITDA
- -101.15×
- Earnings yield
- 3.18%
- Free cash flow yield
- -0.77%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- 0.86%
- Return on assets
- 0.83%
- Return on invested capital
- -0.26%
Financial health
- Debt / equity
- 0×
- Current ratio
- 0.09×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 |
|---|---|---|
| Selling, general, and administrative | 488.39K USD | 151.72K USD |
| Operating expenses | 1.3M USD | 151.72K USD |
| Interest income | 4.93M USD | — |
| Operating income | −1.3M USD | −151.72K USD |
| Net income | 4.19M USD | −151.72K USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- 0.15
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
DMII peers
Continue in GoAI
Research DMIIresearch.disclaimer